BiotechTube

Acalabrutinib + Venetoclax + Obinutuzumab

Phase 1/2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Mantle Cell Lymphoma

Conditions

Mantle Cell Lymphoma, Refractory Lymphoma

Trial Timeline

Jul 2, 2021 → Dec 31, 2027

NCT ID
NCT04855695

About Acalabrutinib + Venetoclax + Obinutuzumab

Acalabrutinib + Venetoclax + Obinutuzumab is a phase 1/2 stage product being developed by AstraZeneca for Mantle Cell Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04855695. Target conditions include Mantle Cell Lymphoma, Refractory Lymphoma.

What happened to similar drugs?

1 of 6 similar drugs in Mantle Cell Lymphoma were approved

Approved (1) Terminated (1) Active (4)
✅Acalabrutinib capsuleAstraZenecaApproved
🔄Pirtobrutinib + Ibrutinib + Acalabrutinib + ZanubrutinibEli LillyPhase 3
🔄Rituximab 375 mg/m^2 + Cyclophosphamide 750 mg/m^2 + Doxorubicin 50 mg/m^2 + VELCADE 1.3 mg/m^2 + Prednisone 100 mg/m^2 + Vincristine 1.4 mg/m^2Johnson & JohnsonPhase 3
🔄Acalabrutinib + Bendamustine + Rituximab + PlaceboAstraZenecaPhase 3
🔄Sonrotoclax + Zanubrutinib + PlaceboBeOne MedicinesPhase 3
❌parsaclisib + rituximab + bendamustine + PlaceboIncytePhase 3

Hype Score Breakdown

Clinical
9
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT05057494Phase 3Active
NCT04855695Phase 1/2Recruiting

Competing Products

20 competing products in Mantle Cell Lymphoma

See all competitors
ProductCompanyStageHype Score
Pirtobrutinib + Brexucabtagene AutoleucelEli LillyPhase 2
42
Obinutuzumab + Glofitamab + PirtobrutinibEli LillyPhase 2
42
enzastaurinEli LillyPhase 2
35
AbemaciclibEli LillyPhase 2
35
Pirtobrutinib + Ibrutinib + Acalabrutinib + ZanubrutinibEli LillyPhase 3
44
Pirtobrutinib + Rituximab + VenetoclaxEli LillyPhase 2
42
Pirtobrutinib and rituximabEli LillyPhase 2
42
gemcitabine + mitoxantrone + rituximabEli LillyPhase 2
35
Rituximab 375 mg/m^2 + Cyclophosphamide 750 mg/m^2 + Doxorubicin 50 mg/m^2 + VELCADE 1.3 mg/m^2 + Prednisone 100 mg/m^2 + Vincristine 1.4 mg/m^2Johnson & JohnsonPhase 3
40
VenetoclaxAbbViePhase 2
35
Ibrutinib + VenetoclaxAbbViePhase 2
35
ABT-199 and Ibrutinib CombinationAbbViePhase 1
29
Venetoclax Oral Tablet [Venclexta]AbbViePhase 2
27
Acalabrutinib capsuleAstraZenecaApproved
43
Acalabrutinib in combination with BR + Acalabrutinib in combination with VRAstraZenecaPhase 1
33
Acalabrutinib + R-CHOP standard of care + Acalabrutinib combination with Rituximab + Acalabrutinib monotherapyAstraZenecaPhase 2
42
Acalabrutinib + Venetoclax + RituximabAstraZenecaPhase 2
39
Acalabrutinib + RituximabAstraZenecaPhase 2
42
Acalabrutinib Treatment A + Acalabrutinib Treatment B + Acalabrutinib Treatment C + Acalabrutinib Treatment DAstraZenecaPhase 1
29
Acalabrutinib + Lenalidomide + Rituximab + ObinutuzumabAstraZenecaPhase 2
39